![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/lipocine-presents-52-week-results-from-lpcn-1148-phase-2-study-in-late-breaking-session-at-easl-congress-2024-302167763.html
https://www.prnewswire.com/news-releases/lipocine-announces-late-breaking-oral-presentation-of-data-from-the-phase-2-study-of-lpcn-1148-at-easl-congress-2024-302139091.html
https://www.prnewswire.com/news-releases/lipocine-announces-completion-of-dosing-in-pivotal-study-of-postpartum-depression-candidate-lpcn-1154-302132497.html
https://www.biospace.com/article/releases/lipocine-announces-positive-lpcn-2401-clinical-results-showing-improved-body-composition-in-participants-with-obesity/#:~:text=As%20adjunct%20therapy%20to%20incretin,and%20accelerate%20muscle%20rebound%20post
https://www.prnewswire.com/news-releases/lipocine-announces-positive-lpcn-2401-clinical-results-showing-improved-body-composition-in-participants-with-obesity-302114311.html
https://www.prnewswire.com/news-releases/lipocine-announces-positive-week-52-results-from-lpcn-1148-phase-2-study-in-patients-with-cirrhosis-302101966.html
https://www.prnewswire.com/news-releases/lipocine-announces-first-cohort-dosed-in-pivotal-study-of-lpcn-1154-302096480.html
https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-full-year-ended-december-31-2023-302082273.html
https://www.prnewswire.com/news-releases/lipocine-to-present-at-36th-annual-roth-conference-302080445.html
https://www.prnewswire.com/news-releases/lipocine-announces-confirmation-of-dosing-regimen-for-pivotal-study-of-lpcn-1154-302053961.html